Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
about
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritisHypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis.Toll-like receptors expressed by synovial fibroblasts perpetuate Th1 and th17 cell responses in rheumatoid arthritis.Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case studyInterleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis--the first 50 years.Targeted therapies in rheumatoid arthritis: Focus on rituximab.SDF-1 signaling: a promising target in rheumatic diseases.The role of human umbilical cord tissue-derived mesenchymal stromal cells (UCX®) in the treatment of inflammatory arthritis.Infliximab for rheumatoid arthritis.Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis.Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha.
P2860
Q24612869-9B18B4DD-635B-41D3-8F81-32F0DD3891D7Q34965451-1B00595B-ADB9-441F-956C-9A700960F3E1Q35189497-8A50F962-A42D-44B4-9B73-0E935EF7D5FEQ36401901-7CA157B8-ECFC-4DB6-9C10-241EDC995877Q36675441-21363D0F-0F34-4010-BAA4-81DAB142ACEAQ37306846-D3A5716F-1A74-472A-B847-C2339315E1E5Q37586832-51C66355-988B-4302-8B4E-788C08D9231DQ38221918-4085E937-F21C-40A0-9CCE-903A870779ADQ41972955-955D0D0B-F756-4C95-810D-E6A418C3B43AQ52856626-1D514427-DB43-41B9-AD51-DC8F8D3C0623Q54340309-D1852DA5-B5D8-4B74-93FA-86D612401315Q54592971-AE737747-B049-4D8E-A462-79012D9FE44A
P2860
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@ast
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@en
type
label
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@ast
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@en
prefLabel
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@ast
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12.
@en
P2093
P2860
P356
P1476
Clinical efficacy of inflixima ...... alpha and IL18 but not CXCL12
@en
P2093
Huizinga TW
Levarht EW
van Laar JM
van Oosterhout M
P2860
P304
P356
10.1136/ARD.2004.024927
P407
P577
2005-04-01T00:00:00Z